Goal
Weight
The peptides readers look up for weight, and whether each can be prescribed or compounded in the U.S. today. Every status below names the FDA document it rests on.
Prescribable now
A once-weekly GLP-1 injection with some of the largest trials of any drug on this site. The trials studied the approved product; most telehealth sellers dispense a compounded version. Read the Semaglutide guide
Wegovy (semaglutide) injection, NDA 215256, approved for chronic weight management.
Source:FDA document, read September 2026.
A once-weekly injection that acts on two gut-hormone receptors. Its obesity trial is among the largest on this site, and a withdrawal trial measured what happens when it stops. Read the Tirzepatide guide
Zepbound (tirzepatide) injection, NDA 217806, approved for chronic weight management.
Source:FDA document, read September 2026.
A once-daily GLP-1 injection, approved for weight management as Saxenda in 2014. Two 56-week trials measured how much weight it took off, and how much of a diet's loss it helped keep off. Read the Liraglutide guide
Saxenda (liraglutide) injection, NDA 206321, approved December 23, 2014 for chronic weight management.
Source:FDA document, read September 2026.
A once-daily GLP-1 tablet, and a small molecule rather than a peptide. Its 72-week phase 3 trial in 3,127 adults measured weight loss against placebo, not against the injected drugs. Read the Orforglipron guide
Foundayo (orforglipron) tablets, NDA 220934, approved April 1, 2026 for chronic weight management.
Source:FDA document, read September 2026.
Sellers for weight
The licensed telehealths we have reviewed that prescribe the peptides above for weight. Each links to the seller and to our review of it.
Disclosure: This Peptide is reader-supported. No link on this site earns a commission today, so nothing here is a paid placement. How we make money.
- Breeze Meds
- Care Bare Rx
- CoreAge Rx
- Strut Health
- Synergy Rx
Ordered by how many of these peptides each seller prescribes, then by name. A partnership never changes the order.
Approved for something else
The FDA has approved these only as a brand-name drug, for a use other than weight, and compounded versions are not permitted. We explain why readers look them up, and link no seller.
Tesamorelin
Approved as a brand only
A daily injection approved for one use: excess belly fat in adults with HIV-associated lipodystrophy. Its trials measured fat around the organs, and its label says it is not a weight-loss drug. Read the Tesamorelin guide
Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions.
Source:FDA document, read September 2026.Also:FDA notice to compounders (March 23, 2020)Drugs@FDA, application 022505Egrifta WR label (DailyMed)
We link no seller for it: only the brand-name product may be prescribed, and compounded versions are not permitted.
Research on weight
- Peptides for Weight Loss: What the Evidence Shows Beyond Semaglutide and TirzepatideThe peptides with real weight-loss evidence are close relatives of the GLP-1 drugs. Several others sold for fat loss have little or no human data behind them.
- Retatrutide: What the Triple-Agonist Trials Show So FarA weekly injection aimed at three receptors, with 24.2% average weight loss at the top phase 2 dose. It is not approved. What the trials measured, and what online products are not.
- Tesamorelin: What the Egrifta Trials Showed, and What They Did NotTesamorelin cut deep belly fat in people with HIV, and the effect faded when they stopped. Its own label calls it weight neutral.
- Tesamorelin Dosage: What the Egrifta Label States and What the Trials GaveThe Egrifta labels state 1.28 mg or 1.4 mg once daily, and every trial used 2 mg. Why three numbers describe one dose, and why no dose exists outside HIV.
- Tesamorelin Side Effects: What the Egrifta Trials and Label RecordedInjection-site reactions, joint and muscle pain, swelling, higher blood sugar and IGF-1 above the normal range. What the label and trials recorded, and in whom.
- Tirzepatide Dosage: The Label's Dose Steps and What the SURMOUNT Trials UsedThe label starts at 2.5 mg a week and climbs in 2.5 mg steps to a 15 mg ceiling. Here is each step, why it exists, and what the trials found at 5, 10 and 15 mg.
- Tirzepatide vs Semaglutide: What the Head-to-Head Trials FoundTwo randomized trials compared the drugs directly. Tirzepatide produced more weight loss in both, and both trials were open-label and paid for by its maker.
- Wegovy Pill: What the Oral Semaglutide Weight Trials ShowedThe daily Wegovy pill cut weight 13.6% against 2.2% on placebo over 64 weeks. What the FDA approved, why the dose is 25 mg, and how it compares with the shot.
- What Happens When You Stop Taking Semaglutide: The Trial Extension DataThree trials stopped the drug on purpose. A year after STEP 1 ended, people had regained about two-thirds of their loss. Here is what each trial measured.